JMIR mHealth and uHealth

Using Digital Signs to Track Mood Episode Activity: Developing and Testing New Ideas

Updated

Abstract

Physiological data from wearables predicted the severity of mood episodes with moderate accuracies ranging from 62% to 85%.

  • The polarity of mood episodes was predicted with moderate accuracy of 70%.
  • Acceleration (ACC), electrodermal activity (EDA), and heart rate (HR) were identified as the most relevant features for predicting mood episode severity.
  • Generalization of predictive models on unseen patients showed overall low accuracy, except for intra-individual models.
  • ACC was associated with increased motor activity, insomnia, and motor inhibition.
  • EDA was linked to aggressive behavior and psychic anxiety.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Conflicts of Interest: GA has received continuing medical education (CME)–related honoraria or consulting fees from Janssen-Cilag, Lundbeck, Lundbeck and Otsuka, and Angelini. IP has received CME-related honoraria, or consulting fees from ADAMED, Janssen-Cilag, and Lundbeck. IG has received grants and served as consultant, advisor or CME speaker for the following identities: Angelini, Casen Recordati, Ferrer, Janssen Cilag, and Lundbeck, Lundbeck-Otsuka, Luye, SEI Healthcare. AG-P has received CME-related honoraria, or consulting fees from Janssen-Cilag, Lundbeck, Casen Recordati and Angelini. MC has received grants and served as consultant, advisor or CME speaker for the following entities: Lundbeck, Esteve, Pfizer. NA has received CME-related financing from Janssen-Cilag, Lundbeck, Adamed, Pfizer, Angelini and Boston Scientific. MB has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of has received honoraria from talks and/or consultancy of Adamed, Angelini, Casen-Recordati, Exeltis, Ferrer, Janssen, Lundbeck, Neuraxpharm, Otsuka, Pfizer and Sanofi. NV has received financial support for CME activities and travel funds from the following entities: Angelini, Janssen-Cilag, Lundbeck, Otsuka. SM has received CME-related honoraria, or consulting fees from Janssen-Cilag, Lundbeck, Lundbeck/Otsuka, and Angelini. A Murru has received grants and served as consultant, advisor or CME speaker for the following entities: Angelini, Idorsia, Lundbeck, Pfizer, Takeda. LS has received CME-related honoraria, or consulting fees from Boehringer -Ingelheim, Janssen, Lundbeck/Otsuka, Sanofi-Aventis. AHY has received honoraria for lectures and advisory boards for all major pharmaceutical companies with drugs used in affective and related disorders. EV has received research support from or served as consultant, adviser or speaker for AB-Biotics, Abbott, Abbvie, Adamed, Angelini, Biogen, Celon, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, GH Research, Glaxo SmithKline, Janssen, Lundbeck, Organon, Otsuka, Rovi, Sage pharmaceuticals, Sanofi-Aventis, Shire, Sunovion, Takeda, and Viatris. DH-M has received CME-related honoraria and served as consultant for Abbott, Angelini, Ethypharm Digital Therapy and Janssen-Cilag. All authors report no financial or other relationship relevant to the subject of this article.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free